Monogram Technologies Inc. Files 8-K Report
| Field | Detail |
|---|---|
| Company | Monogram Technologies Inc. |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, medical-devices
TL;DR
Monogram Tech filed an 8-K, but the details are still under wraps.
AI Summary
On September 4, 2025, Monogram Technologies Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Monogram Technologies Inc. has reported an event to the SEC, which could be material to investors. However, the specific nature of the event is not detailed in this excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of negative or significantly positive material events.
Key Players & Entities
- Monogram Technologies Inc. (company) — Registrant
- September 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 3913 Todd Lane, Austin, TX 78744 (address) — Principal executive offices
- 512-399-2656 (phone_number) — Registrant's telephone number
FAQ
What specific event prompted Monogram Technologies Inc. to file this 8-K report?
The provided excerpt does not specify the exact event, only that it falls under "Other Events" and was reported on September 4, 2025.
What is the principal business of Monogram Technologies Inc.?
Monogram Technologies Inc. is classified under the Standard Industrial Classification code 3841 for "Surgical & Medical Instruments & Apparatus."
When was Monogram Technologies Inc. incorporated?
The company is incorporated in Delaware.
What is the address of Monogram Technologies Inc.'s principal executive offices?
The principal executive offices are located at 3913 Todd Lane, Suite 307, Austin, TX 78744.
What was the former name of Monogram Technologies Inc.?
The former name of the company was MONOGRAM ORTHOPAEDICS INC, with a date of name change on March 5, 2019.
Filing Stats: 1,981 words · 8 min read · ~7 pages · Grade level 18.6 · Accepted 2025-09-05 07:58:03
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MGRM The Nasdaq Stock Mar
Filing Documents
- tm2525352d1_8k.htm (8-K) — 37KB
- 0001104659-25-087631.txt ( ) — 203KB
- mgrm-20250904.xsd (EX-101.SCH) — 3KB
- mgrm-20250904_lab.xml (EX-101.LAB) — 33KB
- mgrm-20250904_pre.xml (EX-101.PRE) — 22KB
- tm2525352d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, Monogram Technologies Inc., a Delaware corporation (the " Company " or " Monogram "), is party to that certain Agreement and Plan of Merger, dated July 11, 2025, by and among the Company, Zimmer Biomet Holdings, Inc., a Delaware corporation (" Zimmer Biomet "), and Honey Badger Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Zimmer Biomet (" Merger Sub "), as amended by that certain First Amendment to Agreement and Plan of Merger, dated August 27, 2025, by and between the Company and Zimmer Biomet (as amended, the " Merger Agreement "). The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act "), Merger Sub will merge with and into the Company (the " Merger "), with the Company surviving the Merger as a wholly owned subsidiary of Zimmer Biomet. As part of the parties' continuing cooperation with the regulatory review of the Merger, on September 4, 2025, Zimmer Biomet, as the acquiring party, in consultation with the Company, voluntarily withdrew its pre-merger Notification and Report Form filed pursuant to the HSR Act, in order to provide the Federal Trade Commission (the " FTC ") with additional time to review the Merger. On the same date, in accordance with the regulations under the HSR Act, Zimmer Biomet resubmitted its pre-merger Notification and Report Form, commencing a new 30-day waiting period under the HSR Act, which will expire on October 6, 2025, at 11:59 p.m., Eastern Time, unless terminated earlier or extended. Wit hdrawing and refiling pre-merger notifications is a standard procedure in order to provide additional time for antitrust review of certain transactions. The Company and Zimmer Biomet continue to work constructively with FTC staff i